BusinessActinium Pharmaceuticals to Present at 29th Annual ROTH ConferenceBy Nasdaq OMXMar 7, 2017, 12:01 PM UTC
BusinessKura Oncology Reports Updated Clinical Activity Data in Ongoing Phase 2 Trial for TipifarnibBy Nasdaq OMXMar 6, 2017, 12:30 PM UTC
BusinessImmune Design to Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at the American Association for Cancer Research (AACR) Annual Meeting 2017By Nasdaq OMXMar 1, 2017, 10:24 PM UTC
BusinessActinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology PlatformBy Nasdaq OMXFeb 28, 2017, 12:01 PM UTC
BusinessActinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology PlatformBy Nasdaq OMXFeb 28, 2017, 12:01 PM UTC
BusinessKura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017By Nasdaq OMXFeb 27, 2017, 12:30 PM UTC
BusinessImmune Design Receives Orphan Drug Designation for G100 Intratumoral Product CandidateBy Nasdaq OMXFeb 22, 2017, 1:00 PM UTC
BusinessSurgical Oncologists and Oncology Health Care Professionals Come Together in Seattle to Discuss Groundbreaking Research and Advancements in the Surgical Treatment of CancerBy Nasdaq OMXFeb 15, 2017, 4:22 PM UTC
